IPPRA / Grant Monitor

2026-11-05
← Board

Prototype development for Battlefield Wound Infection Prevention and Treatment (BWI P&T) Barrier Combination

HT9427-26-R-E020 · DEFENSE HEALTH AGENCY (DHA) · DEFENSE HEALTH AGENCY

biomedical clinical public health materials manufacturing

Closes
2026-11-06 · 1 d
Award ceiling
—
Award floor
—
Program funding
—
Expected awards
—
Cost sharing
No
Posted
2026-10-19
Instrument
—
Characterization · gpt-5.4-mini · 2026-10-20

Funds development of a battlefield wound infection prevention/treatment barrier-combination prototype with antimicrobial or antifungal properties and FDA approval or clearance for military medical use.

Funds
applied research
University
ineligible
physical sciences
minor
engineering
substantial
life biomedical
central

⚑ Federal contract / prototype OTA solicitation; not a standard grant · Requires a combination wound treatment product with barrier plus antimicrobial/antifungal function · Final product must have FDA approval or clearance · One award stated in notice

Unit fits — one characterization, each unit's own rules

Tom Love Innovation Hub 45 partial funds applied research; prototyping/demonstration stage; deep-tech content
IPPRA 15 none university cannot apply directly (ineligible)
Physical Sciences & Engineering (demo) 15 none university cannot apply directly (ineligible)

Description

This RPP is being issued by the Defense Health Agency Contracting Activity (DHACA), in support of the Defense Health Agency’s Portfolio Acquisition Executive (PAE) Medical Products (MP) Warfighter Protection (WPAC) & Acute Care Program Management Office (PMO) Care located in Frederick, Maryland at Fort Detrick. The Warfighter Protection and Acute Care Project Management Office (WPAC PMO) has a requirement for the development of a Barrier Combination product. The Barrier Combination product is defined as being composed of both a physical barrier to protect a wound and an antibacterial and/or antifungal activity released from the barrier to prevent the spread of organisms and avoid systemic infections. This RPP will result in one award to develop the Battlefield Wound Infection Prevention and Treatment (BWI P&T) Barrier Combination (BC) prototype product. The final product MUST be a combination wound treatment that includes a barrier component that is either infused or impregnated with antimicrobial and/or antifungal properties and have U.S. Food Drug Administration (FDA) approval (or clearance). The award, as a result of this RPP, will be awarded under the authority of prototype Other Transaction Authority (pOTA) 10 U.S.C. 4022.

Eligibility

Applicant restrictions (federal contract). Set-aside: . Notice type: Solicitation. Organization: DEPT OF DEFENSE / DEFENSE HEALTH AGENCY (DHA) / DEFENSE HEALTH AGENCY.

Apply

View on Grants.gov →

Proposal brief SEE AN EXAMPLE →

A one-page internal memo: fit assessment, submission requirements, document scaffold, and next steps dated back from the deadline — tailored to your project idea if you add one.

ONE LLM CALL (~1¢) · CACHED · REQUIRES STAFF KEY

Proposal shell · Department of Defense (BAA-style) conventions SEE A DOD EXAMPLE →

Funder-faithful document skeletons — Department of Defense (BAA-style)'s document set with section headings, page limits, reviewer guidance, and writing prompts; add a project idea to get [DRAFT] starter bullets. Download as .md for Word or Overleaf.

ONE LLM CALL (~2-3¢) · CACHED · SCAFFOLDING, NOT GHOSTWRITING